UL Stock Analysis: Unilever | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 137.144m USD | 12M Return: -5.2% | US9047678035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 269M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Unilever PLC is a global fast-moving consumer goods (FMCG) company headquartered in London, with operations spanning Asia Pacific, Africa, the Americas, and Europe. The business is organized into four segments: Beauty & Wellbeing, Personal Care, Home Care, and Foods, covering categories such as hair and skin care, deodorants and oral care, laundry and household cleaning products, and cooking aids and condiments. Unilever sells its products under a broad portfolio of well-known brands, including Dove, Hellmanns, Knorr, Vaseline, TRESemmé, Sunsilk, and Ponds, among others. Founded in 1860, the company has built a global presence through a multi-brand, multi-category strategy that targets both mass-market consumers and prestige segments such as Dermalogica, Paulas Choice, and Nutrafol.
As an FMCG operator, Unilevers business model is built on high-volume, frequently replenished product categories that generate relatively predictable, recurring revenue streams, which is typical of the consumer staples sector. The companys segment structure reflects a deliberate balance between personal consumption categories (beauty and personal care), household essentials (home care), and food products, allowing it to diversify demand cycles across geographies and consumer spending patterns.
- Prestige Beauty brands accelerate Beauty and Wellbeing growth
- Ice cream demerger sharpens portfolio and margin focus
- Emerging market FX headwinds pressure reported revenue
| Net Income: 5.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.69 > 1.0 |
| NWC/Revenue: -16.18% < 20% (prev -9.89%; Δ -6.30% < -1%) |
| CFO/TA 0.11 > 3% & CFO 8.53b > Net Income 5.64b |
| Net Debt (27.6b) to EBITDA (10.5b): 2.62 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.18b) vs 12m ago -13.05% < -2% |
| Gross Margin: 42.20% > 18% (prev 44.14%; Δ -1.93% > 0.5%) |
| Asset Turnover: 60.62% > 50% (prev 78.65%; Δ -18.02% > 0%) |
| Interest Coverage Ratio: 9.13 > 6 (EBIT TTM 9.42b / Interest Expense TTM 1.03b) |
| A: -0.10 (Total Current Assets 21.4b - Total Current Liabilities 28.9b) / Total Assets 76.9b |
| B: 0.60 (Retained Earnings 45.9b / Total Assets 76.9b) |
| C: 0.12 (EBIT TTM 9.42b / Avg Total Assets 76.5b) |
| D: 0.28 (Book Value of Equity 16.2b / Total Liabilities 58.6b) |
| Altman-Z'' = 2.42 = A |
| DSRI: 1.71 (Receivables 10.2b/7.69b, Revenue 46.4b/59.8b) |
| GMI: 1.05 (GM 44.14% / 42.20%) |
| AQI: 0.99 (AQ_t 0.60 / AQ_t-1 0.60) |
| SGI: 0.78 (Revenue 46.4b / 59.8b) |
| TATA: -0.04 (NI 5.64b - CFO 8.53b) / TA 76.9b) |
| Beneish M = -2.57 (Cap -4..+1) = A |
As of August 12, 2026, the stock is trading at USD 62.37 with a total of 2,076,340 shares traded. Over the past week, the price has changed by -1.85%, over one month by +2.30%, over three months by +10.93% and over the past year by -5.18%.
Current recommended Stop Loss: 59.30 (which is 4.9% or 2.4 ATR below the current price).
Unilever has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy UL.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 73.6 | 18% |
Market Cap EUR = 119b (137b USD * 0.8664 USD.EUR)
P/E Trailing = 21.5797
P/E Forward = 17.5439
P/S = 2.7093
P/B = 7.6675
P/EG = 11.7035
Revenue TTM = 46.4b EUR
EBIT TTM = 9.42b EUR
EBITDA TTM = 10.5b EUR
Long Term Debt = 24.1b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 8.14b EUR (from shortTermDebt, last quarter)
Debt = 33.4b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.33b
Net Debt = 27.6b EUR (calculated: Debt 33.4b - CCE 5.87b)
Enterprise Value = 146b EUR (119b + Debt 33.4b - CCE 5.87b)
Interest Coverage Ratio = 9.13 (Ebit TTM 9.42b / Interest Expense TTM 1.03b)
EV/FCF = 20.23x (Enterprise Value 146b / FCF TTM 7.24b)
FCF Yield = 4.94% (FCF TTM 7.24b / Enterprise Value 146b)
FCF Margin = 15.61% (FCF TTM 7.24b / Revenue TTM 46.4b)
Net Margin = 12.17% (Net Income TTM 5.64b / Revenue TTM 46.4b)
Gross Margin = 42.20% ((Revenue TTM 46.4b - Cost of Revenue TTM 26.8b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.90 (Enterprise Value 146b / Total Assets 76.9b)
Interest Expense / Debt = 3.09% (Interest Expense 1.03b / Debt 33.4b)
Taxrate = 31.05% (2.59b / 8.33b)
NOPAT = 6.49b (EBIT 9.42b * (1 - 31.05%))
Current Ratio = 0.74 (Total Current Assets 21.4b / Total Current Liabilities 28.9b)
Debt / Equity = 2.06 (Debt 33.4b / totalStockholderEquity, last quarter 16.2b)
Debt / EBITDA = 2.62 (Net Debt 27.6b / EBITDA 10.5b)
Debt / FCF = 3.81 (Net Debt 27.6b / FCF TTM 7.24b)
Total Stockholder Equity = 17.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.38% (Net Income 5.64b / Total Assets 76.9b)
RoE = 32.47% (Net Income TTM 5.64b / Total Stockholder Equity 17.4b)
RoCE = 22.71% (EBIT 9.42b / Capital Employed (Equity 17.4b + L.T.Debt 24.1b))
RoIC = 12.05% (NOPAT 6.49b / Invested Capital 53.9b)
WACC = 4.33% (E(119b)/V(152b) * Re(4.95%) + D(33.4b)/V(152b) * Rd(3.09%) * (1-Tc(0.31)))
Discount Rate = 4.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.27 | Cagr: -7.34%
[DCF] Terminal Value 76.58% ; FCFF base≈6.99b ; Y1≈7.56b ; Y5≈9.29b
[DCF] Fair Price = 53.25 (EV 142b - Net Debt 27.6b = Equity 115b / Shares 2.15b; r=8.35% [WACC [floored]]; 5y FCF grow 9.30% → 2.50% )
EPS Correlation: -19.39 | EPS CAGR: -5.38% | SUE: 0.0 | # QB: 0
Revenue Correlation: -9.84 | Revenue CAGR: -1.53% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2025-12-31): EPS=2.94 | Chg30d=+2.36% | Revisions=+25% | GrowthEPS=-12.3% | GrowthRev=-16.8%
EPS next Year (2026-12-31): EPS=3.17 | Chg30d=+0.22% | Revisions=+17% | GrowthEPS=+3.0% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +29% (up=3, down=1)